Session Item

To analyze the results in terms of overall survival (OS), cancer specific survival (CSS), local control (LC), cosmesis and toxicity in patients (pts) with non-melanoma skin cancer (NMSC) treated with high-dose-rate brachytherapy (HDR-BT) treatment, plesiotherapy modality with radical or adjuvant intention in our hospital.

Retrospective study of 280 pts with 343 NMSC lesions, Tis (4.4%), T1 (77.6%) and T2 (18.1%) stage treated from May 2015 to September 2018. The median age was 76,8 (29-97) 50,1% >80 years-old; 62.1% males. ECOG 0 (52,5%). NMSC lesions were treated with Valencia applicators (35%), flaps (15,7%), silicone custom-made moulds (47,5%) and thermoplastic masks (1,7%). Hipofracionated treatment (42 Gy;6 Gy/fraction;2 week-days) with an equivalent 2 Gy dose (a/b 10) of 56 Gy was the most used scheme. All the lesions were limited 3-4 mm depth. Basal-cell carcinoma (87,2%) and face (69,1%) were the most frequent histological type and location respectively. Kaplan-Meier curves have been used for the statistical analysis of survival. Treatment-related toxicity was assessed using RTOG and the NCI-Common Terminology Criteria for Adverse Events guidelines.

The median follow-up was 50,62 months (range 3-106). To 3 years the OS, CSS, LRFS and LC was 85,3%, 100%, 97,3% and 93,3% (23 lesions locally relapse) respectively. Differences in OS were observed in ECOG and age >80 years (p: 0.00). No differences were observed in LC. 6,4% had severe acute skin toxicity. Conjunctival toxicity appeared in 7,6% pts. Cosmetic results were considered as excellent/good in 93,3% pts.

In patients with NMSC early stage, plesiotherapy is a good alternative treatment for non-surgical patients. Plesiotherapy treatment provides excellent long-term results for local control and cosmesis which is a safe and attractive treatment option.